FDA
-
-
-
-
-
-
-
TherapeuticsMD Completes the Divestiture of vitaCare Prescription Services to GoodRx in a Cash Transaction Valued at $150 Million
-
-
-
-
-
-
-
TherapeuticsMD (TXMD) Receives Approval from FDA of sNDA for BIJUVA
-
-
-
-
-
-
-
TherapeuticsMD (TXMD) Appoints Hugh O’Dowd as CEO
-
-
-
-
-
-
-
TherapeuticsMD Announces Appointment of Hugh O’Dowd as President
-
-
-
-
-
-
-
TherapeuticsMD (TXMD) Tops Q1 EPS by 1c, Revenues Beat
-
-
-
-
-
-
-
TherapeuticsMD and Theramex Announce the Approval of BIJUVE® Capsules Indicated for Hormone Replacement Therapy in the United Kingdom and Under the Trade Name BIJUVA® in Belgium
-
-
-
-
-
-
-
TherapeuticsMD (TXMD) Announces Underwritten Public Offering of its Common Stock
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

